SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment

Most tumors initially respond to cytotoxic treatments, but acquired resistance often follows. The tumor microenvironment (TME) is a major barrier to clinical success by compromising therapeutic efficacy, and pathological relevance of multiple soluble factors released by a therapeutically remodeled T...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Y, Zhu, D, Chen, F, Qian, M, Wei, H, Chen, W, Xu, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994019/
https://www.ncbi.nlm.nih.gov/pubmed/26751775
http://dx.doi.org/10.1038/onc.2015.494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994019/
https://www.ncbi.nlm.nih.gov/pubmed/26751775
http://dx.doi.org/10.1038/onc.2015.494

Ejemplares similares